Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05502133 · ClinicalTrials.gov registry record
Identification of Acute Intermittent Porphyria Modifying Genes
A clinical trial of Acute Intermittent Porphyria (AIP), sponsored by Icahn School of Medicine at Mount Sinai.
- Recruiting
- Registry status
- 150
- Enrollment target
- 1
- Study location
NCT05502133 is a study of Acute Intermittent Porphyria (AIP) that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 150 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05502133, a study of Acute Intermittent Porphyria (AIP), is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.
- RECRUITING
- Registry status
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.
Conditions Studied
Study Locations (1)
New York
- Icahn School of Medicine at Mount Sinai - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-09-23 |
| Est. Completion | 2026-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05502133
The ClinicalTrials.gov registry entry for NCT05502133 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Acute Intermittent Porphyria (AIP) appearing as the primary indexed condition, and to 0 interventions.
NCT05502133 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05502133 about?
NCT05502133 is a clinical study titled "Identification of Acute Intermittent Porphyria Modifying Genes". This study proposes to identify the predisposing/protective modifying genes that underlie the acute attacks in symptomatic patients with Acute Intermittent Porphyria (AIP), an autosomal dominant inborn error of heme biosynthesis.
What is the current status of trial NCT05502133?
This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2022-09-23. Estimated completion is 2026-06.
What conditions does trial NCT05502133 study?
This clinical trial studies the following conditions: Acute Intermittent Porphyria (AIP).
Who is sponsoring clinical trial NCT05502133?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05502133 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.